Foundayo vs Zepbound: two different drugs, two different routines

Before you read. This guide is educational and does not replace your Medication Guide, pharmacist, prescriber, diagnosis, or emergency care. It deliberately does not say which of these two medicines is better, or better for you — there is no head-to-head trial to support such a claim, and the decision belongs to the clinician who writes the prescription. Do not start, stop, switch, or change the dose of anything based on this page.

Quick answer

These are not two versions of the same drug. Foundayo is orforglipron: a small non-peptide molecule, taken as a tablet once a day, with or without food, that activates the GLP-1 receptor. Zepbound is tirzepatide: a 39-amino-acid peptide injected under the skin once a week, at any time of day, that activates two receptors — GIP as well as GLP-1. One target versus two, swallowed versus injected, daily versus weekly.

Both are approved for weight management in adults alongside a reduced-calorie diet and increased physical activity. Both carry the same boxed warning about thyroid C-cell tumours, the same two contraindications, and the same broad family of gastrointestinal side effects. What differs most concretely, and what this page spends its time on, is the shape each one imposes on an ordinary week.

Track either routine in Takely

What are these two drugs, exactly?

Foundayo (orforglipron) was approved by the FDA on 1 April 2026. Its label describes it as a GLP-1 receptor agonist indicated, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain that reduction long term in adults with obesity, or in adults with overweight who have at least one weight-related condition. We cover the drug on its own terms in what Foundayo is and how it is dosed.

Zepbound (tirzepatide) has been approved since 2023. Its label describes it as a glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist, with the same weight-management indication plus a second one Foundayo does not have: the treatment of moderate to severe obstructive sleep apnoea in adults with obesity.

That second indication is the first genuine, label-level difference between them, and it is worth naming early because it is not a matter of degree. If sleep apnoea is part of the picture, only one of these two carries an approved indication for it.

Table 1 — mechanism

	Foundayo (orforglipron)	Zepbound (tirzepatide)
Receptor targets	GLP-1 receptor	GIP receptor and GLP-1 receptor
Molecule type	Small molecule, non-peptide	Peptide, 39 amino acids, based on the GIP sequence with aminoisobutyric acid at positions 2 and 13
Molecular weight	902.0 g/mol (orforglipron calcium)	4,813.53 Da (formula C225H348N48O68)
Route this makes possible	Oral — survives the digestive tract without an absorption enhancer	Subcutaneous injection — a peptide this size is not orally viable
Bioavailability	About 77% after a 0.8 mg oral dose	Not applicable in the same sense; delivered subcutaneously
Time to peak concentration	4 to 8 hours after the dose	Not stated in the same terms; steady state reached after 4 weeks of weekly dosing
Elimination half-life	Roughly 29 to 49 hours	Approximately 5 days
Approved indications	Chronic weight management in adults	Chronic weight management in adults; moderate to severe obstructive sleep apnoea in adults with obesity
Boxed warning	Thyroid C-cell tumours	Thyroid C-cell tumours
Contraindications	Personal or family history of medullary thyroid carcinoma; MEN 2; serious hypersensitivity	Personal or family history of medullary thyroid carcinoma; MEN 2; serious hypersensitivity

Two things in that table are easy to skim past.

The dual versus single receptor difference is real chemistry, and it is the reason tirzepatide is usually described as a different class of agent rather than a stronger GLP-1. What that difference produces in any individual person is not something a mechanism table can tell you, and we are not going to pretend otherwise.

The half-life difference explains the dosing frequency rather than the other way round. Roughly 29 to 49 hours supports a daily tablet. Approximately 5 days supports a weekly injection. Neither number is a quality rating.

The boxed warnings deserve one note. Both concern thyroid C-cell tumours, but the reasoning differs. Zepbound's warning states that tirzepatide causes thyroid C-cell tumours in rats and that whether it does so in humans is unknown. Foundayo's is unusual: orforglipron is not pharmacologically active in rats or mice and did not produce tumours in rodents, but because rodent C-cell tumours are considered a GLP-1-receptor-dependent effect and orforglipron is active at the human receptor, the label states the human relevance has not been determined. Same conclusion, arrived at from opposite directions.

Table 2 — administration

	Foundayo (orforglipron)	Zepbound (tirzepatide)
Form	Tablet, swallowed whole	Subcutaneous injection
Frequency	Once daily	Once weekly
Time of day	Not restricted by the label	Any time of day
Food	With or without food	With or without meals
Where it goes	Swallowed; do not break, crush, or chew; no more than one tablet per day	Injected into the abdomen or thigh; the back of the upper arm if someone else is injecting; rotate sites
Strengths	0.8, 2.5, 5.5, 9, 14.5, 17.2 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Starting dose	0.8 mg once daily	2.5 mg once weekly for 4 weeks — for initiation only, not approved as a maintenance dose
Escalation	To 2.5 mg after at least 30 days, then 5.5 mg after at least 30 days; may then step to 9, 14.5, or 17.2 mg after at least 30 days on the current dose, based on response and tolerability	To 5 mg after 4 weeks, then in 2.5 mg increments after at least 4 weeks on the current dose
Maximum dose	17.2 mg once daily	15 mg once weekly
Moving the dose	No day-of-week question arises	The day of the week can be changed provided at least 3 days (72 hours) separate two doses
Missed dose, per label	Take as soon as possible; do not double up the next dose. If 7 or more consecutive doses are missed, the label directs the prescriber to reinitiate escalation at a lower dose	Take as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip it and take the next dose on the regularly scheduled day
Storage	Room temperature, 20–25 °C; light sensitive — keep in the original bottle and carton	Refrigerated, 36–46 °F (2–8 °C), not frozen; Lilly's patient guidance allows up to 21 days at room temperature up to 86 °F (30 °C) if refrigeration is unavailable, after which it should not go back in the fridge
Sharps	None	Yes — used devices need proper disposal

The escalation columns are the ones people misread. Both drugs step up slowly and for the same stated reason — to reduce the risk of gastrointestinal reactions — but they count in different units. Foundayo counts in 30-day blocks; Zepbound counts in 4-week blocks. And Foundayo's upper steps are written permissively ("may be increased"), which means the ceiling is a judgement, not a destination. Neither schedule is a menu. Follow the one your prescriber wrote.

A note on the missed-dose rows. They are in the table because the two labels genuinely say different things, not so you can act on them. If you miss a dose of either medicine, the instruction that applies to you is the one from your own prescriber or pharmacist, who knows your dose, your history, and what else you take. Nothing on this page tells you to take, skip, delay, split, or double anything.

Table 3 — what each one asks of your week

This is the part a mechanism table cannot capture, and in practice it is what most people are actually comparing.

	Foundayo (orforglipron)	Zepbound (tirzepatide)
Number of decisions per week	7	1
What a "good week" requires	Remembering a tablet on seven separate days	Remembering one injection on one chosen day
Failure mode	A quietly skipped day nobody notices	A forgotten week, noticed late
Fridge	Not needed	Needed
Travel	A bottle of tablets	Cold chain to plan, plus sharps disposal at the other end
Needles	None	Yes, weekly
Flexibility built into the label	Any time of day, with or without food	Any time of day, with or without meals; the weekly day can be moved with at least 72 hours between doses
What it feels like on a bad-stomach day	A decision you face this morning	A decision you made on Sunday
Oral hormonal contraception	Non-oral method or added barrier for 30 days after starting and 30 days after each escalation	Non-oral method or added barrier for 4 weeks after initiation and 4 weeks after each escalation

The last row is the one that surprises people, and it applies to both drugs. Both labels warn that delayed gastric emptying can affect the absorption of oral medicines, and both give explicit contraception guidance tied to each dose escalation, not just to starting the drug. The windows are worded slightly differently — 30 days versus 4 weeks — and both are conversations to have before the first prescription rather than after the third dose step.

Neither column of that table is the easy one. A daily tablet removes the fridge, the needle and the cold chain, and replaces them with six extra chances a week to forget. A weekly injection collapses the whole thing into one act and makes that act expensive to miss. Which failure mode you can live with is a question about your life, not about the drugs, and it is worth answering honestly before your appointment rather than optimistically.

If you already have a routine on either shape, Takely can track a daily tablet or a weekly injection and keep a private record of how the days actually went. And if the comparison you are really making is pill versus pen within the semaglutide family instead, the pill-versus-pen trade in the semaglutide family covers that directly.

Whichever shape your prescription takes. Takely logs doses, dose-step dates, and how each day went — the three things a follow-up appointment always asks about. Open Takely →

Is one more effective than the other?

We cannot tell you, and neither can anyone who has only read the trial results.

As of 6 August 2026, no head-to-head trial of orforglipron against tirzepatide appears on ClinicalTrials.gov. Each drug's approval rests on its own placebo-controlled programme:

	Foundayo	Zepbound
Trial without type 2 diabetes	NCT05869903 (ATTAIN-1), 72 weeks, 3,127 adults	NCT04184622 (SURMOUNT-1), 72 weeks, 2,539 adults
Trial with type 2 diabetes	NCT05872620 (ATTAIN-2), 72 weeks, 1,613 adults with BMI 27 or higher	NCT04657003 (SURMOUNT-2), 72 weeks, 938 adults with BMI 27 or higher
Comparator	Placebo	Placebo

Different participants, different sites, different years, different protocols. Lining up a number from ATTAIN-1 against a number from SURMOUNT-1 and calling the larger one the winner is a cross-trial comparison, and it is not evidence about either drug relative to the other. Plenty of pages on the internet do exactly this. We are not going to.

We also do not print the headline weight-change figures from either programme. They are trial averages under trial conditions with dietary and activity counselling built in, they say nothing about any individual, and quoting them next to each other would create precisely the false comparison described above. The numbers are in the labels' clinical studies sections and in the published papers, all linked at the bottom — read them there, in context, and take the question of what is realistic for you to your prescriber.

Do the side effects differ?

Broadly the same family, with one obvious extra on the injectable side.

Both labels report gastrointestinal reactions as the dominant category — nausea, diarrhoea, vomiting, constipation, abdominal pain, dyspepsia — and both describe slow escalation as the strategy for reducing them. Zepbound's label adds injection site reactions, reported in 6% to 8% of treated patients across doses versus 2% on placebo. Foundayo, being a tablet, has no equivalent row.

The warnings and precautions lists overlap heavily. Both carry acute pancreatitis, severe gastrointestinal reactions, acute kidney injury due to volume depletion, acute gallbladder disease, hypersensitivity reactions, hypoglycaemia when combined with insulin or an insulin secretagogue, diabetic retinopathy complications in type 2 diabetes, and pulmonary aspiration during anaesthesia or deep sedation. Zepbound's list adds a device-specific instruction never to share a KwikPen between patients.

Both labels also state that using the medicine alongside another GLP-1 receptor agonist is not recommended — which, read together, means these two are not intended to be combined.

One difference is specific to Foundayo and worth flagging because it has no Zepbound counterpart: because orforglipron is metabolised through CYP3A4, its label caps the dose at 9 mg daily when used with a strong CYP3A4 inhibitor, advises avoiding strong CYP3A4 inducers and strong CYP3A4 inhibitors that also inhibit OATP1B, and says simvastatin should not exceed 20 mg daily alongside it. If you take several medicines, that is a pharmacist conversation.

We are not reproducing both adverse-reaction tables side by side here for the same reason we are not comparing efficacy numbers: the percentages come from different trials with different populations and different placebo rates, so putting them in adjacent columns invites a comparison the data does not support. Each table is in its own label, linked below.

What this page does not compare

Three things, deliberately.

Cost. It moves constantly and depends on your insurance more than on the drug. We keep a dated, source-linked breakdown of what Foundayo costs; Zepbound's pricing has its own programmes and its own moving parts.

Which one suits you. Your history, your other prescriptions, your other conditions, your insurance formulary, and whether sleep apnoea is in the picture all bear on this, and none of them are visible from here.

Anything about switching. Neither label's instructions for changing therapy are written for patients to apply, and we are not going to summarise them as if they were.

What is unknown

Relative efficacy. No head-to-head trial exists, so there is no evidence-based answer.
Relative tolerability. Same reason. Cross-trial discontinuation rates are not comparable.
Long-term outcomes for orforglipron. It was approved in April 2026; its published trials run to 72 weeks. Tirzepatide has a longer record simply by virtue of having been approved in 2023.
How either performs for you specifically. Trial averages do not transfer to individuals, in either direction.

How to make the appointment more useful

If you are weighing these two, the productive thing to bring is not a preference but a constraint. Something like: "I share a fridge at work and travel most weeks." Or: "I already forget a daily tablet I've taken for years." Or: "I've been told I have sleep apnoea." Or: "I take a CYP3A4 inhibitor." Each of those genuinely narrows the choice on the evidence in the two labels — which is more than a comparison table can do, including this one.

Frequently asked questions

Is Foundayo the same as Zepbound?

No. Foundayo is orforglipron, a small non-peptide molecule taken as a daily tablet that activates the GLP-1 receptor. Zepbound is tirzepatide, a 39-amino-acid peptide injected weekly that activates both the GIP and GLP-1 receptors. They are different molecules with different administration routes and different receptor targets.

Which works better, Foundayo or Zepbound?

There is no head-to-head trial, so there is no evidence-based answer. Each drug was tested against placebo in its own programme, and results from separate trials cannot be compared to each other. Your prescriber is the right person to weigh the two for your situation.

What is the difference between orforglipron and tirzepatide?

Orforglipron is a small-molecule GLP-1 receptor agonist with a half-life of roughly 29 to 49 hours, taken orally once daily. Tirzepatide is a peptide that agonises both the GIP and GLP-1 receptors, with a half-life of approximately 5 days, injected subcutaneously once weekly.

Can I take Foundayo and Zepbound together?

Both labels state that concomitant use with another GLP-1 receptor agonist is not recommended. This is a question for your prescriber, not something to try.

Does Foundayo need refrigeration like Zepbound?

No. Foundayo tablets are stored at room temperature, 20–25 °C, in the original bottle and carton because the drug is light sensitive. Zepbound is stored in the refrigerator at 36–46 °F (2–8 °C); Lilly's patient guidance allows up to 21 days at room temperature up to 86 °F if refrigeration is unavailable, after which it should not be returned to the fridge.

Do both have a boxed warning?

Yes, both concern the risk of thyroid C-cell tumours, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The underlying rodent findings differ, which is worth reading in each label rather than summarising.

Is one approved for sleep apnoea?

Zepbound carries an approved indication for moderate to severe obstructive sleep apnoea in adults with obesity. Foundayo does not.

Do both affect oral contraception?

Both labels give guidance because delayed gastric emptying can affect oral drug absorption. Foundayo's label advises switching to a non-oral method or adding a barrier method for 30 days after starting and 30 days after each dose escalation. Zepbound's advises the same approach for 4 weeks after initiation and 4 weeks after each escalation. Raise this before the first prescription.

Primary sources and further reading

Labels are revised. Everything on this page was checked against the sources above on 6 August 2026. Check the current label and ask your clinician or pharmacist about your own prescription.